The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
As HBsAg clearance is uncommon in chronic hepatitis B (CHB) patients on nucleoside analogues
(NAs) therapy. The purpose of this study is to optimize HBsAg clearance in CHB Patients with
sequential treatment of pegylated interferon alpha and NAs.
Phase:
Phase 4
Details
Lead Sponsor:
Third Affiliated Hospital, Sun Yat-Sen University
Collaborators:
First People's Hospital of Foshan Peking University Shenzhen Third People's Hospital